Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea

[cafead]

via When Roche and Genentech’s eye drug Vabysmo snared approval in January, it knocked out two of its chief rival’s indications in one fell swoop. Now, the bispecific antibody is muscling in on more of Eylea’s turf with data showing it can go toe-to-toe in a vision-threatening condition that affects more than 1 million people in the U.S.

article source